Remote Magnetic Navigation prominently featured on the HRS 2009 program
ST. LOUIS, May 11 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq:
STXS) said today that the Heart Rhythm 2009 formal program contains 21 podium
and poster presentations in which its Niobe system is either featured or
discussed regarding the treatment of complex cardiac arrhythmias. These
presentations include new efficacy data on the use of Stereotaxis' partnered
magnetic irrigated catheter at centers in Copenhagen and Hamburg.
Xu Chen, MD from Rigshospitalet in Copenhagen will present "Acute and
long-term outcomes of remote magnetic navigation for ablation of atrial
fibrillation using a magnetic irrigated ablation catheter" at a session
beginning at 10:30am on Friday, May 15, in Room 162. At the same session, Erik
Weissner of Asklepios Klinik St. Georg in Hamburg will present "Magnetically
navigated remote pulmonary vein isolation utilizing the second generation 3.5
mm magnetic irrigated tip catheter."
Also, Tamas Szili-Torok, MD of Erasmus Medical Center in Rotterdam and
Jinjin Wu, MD of the German Heart Center in Munich will present at Stereotaxis
Booth # 778 their experiences with the Niobe Remote Magnetic Navigation System
and the treatment of arrhythmias in children. These booth presentations are
separate from their independent conference presentations on the same subjects.
At Stereotaxis' booth, Dr. Szili-Torok will speak at 10:00am on Friday;
his presentation is titled, "Magnetic Navigation for the Treatment of
Pediatric Complex Congenital Arrhythmias." Dr. Wu will present at 3:00pm on
Friday with "Mapping of Atrial Tachycardia: Remote Navigation in
Post-Operative Patients with Congential Heart Disease." These presentations
will provide a forum for clinicians to share their pediatric experiences and
techniques, and demonstrate the growing interest of pediatric
electrophysiologists in adding magnetic navigation to their cardiology
services.
Against this backdrop of clinical experience, Stereotaxis' Booth # 778
will showcase the simplicity, safety, and efficacy of the Niobe Remote
Magnetic Navigation system, the enhanced productivity and procedural
efficiency enabled by Navigant 3.0 with QuikCAS, and the full Odyssey
information management solution. This includes the new Odyssey Workstation 3.0
software and the Odyssey Cinema(TM) data management system for remote viewing
and recording of live interventional cases. This showcase will provide the
most comprehensive interactive demonstration of the full Odyssey solution to
date, providing clinicians with an opportunity to experience how Odyssey can
enhance their institutions' EP practice:
-- At two clinical forums during the conference, participants will be
able to view and control the playback of complete EP cases on laptops
connected to the Odyssey Cinema server, underscoring the unprecedented
opportunities for training and sharing of best practices enabled by
this peerless technology.
-- An Odyssey Connect network link will enable clinicians to use an
Odyssey Workstation in Booth # 778 to remotely control a catheter in a
Niobe lab in the company's St. Louis headquarters, 1,200 miles away.
-- The Odyssey Workstation will be available with a new, state-of-the-art
QuadHD display. Quad HD provides four times the resolution of prior,
high-definition displays, providing an incredible level of patient
detail.
"With our Odyssey Cinema product, we believe that we are building the
first true networked clinical environment that can improve care, enhance
training and education, maximize cath-lab efficiency, promote best practices
and drive hospital referrals," said Michael P. Kaminski, Stereotaxis'
President and Chief Executive Officer. "We are pleased with the progress we've
made and will continue our investment in Odyssey sales and marketing to take
full advantage of our first mover position in this space.
"We also look forward to highlighting the impressive new clinical results
that have been achieved with the Niobe Remote Magnetic Navigation system.
Stereotaxis' routine appearance in so many presentations and posters speaks to
the widespread adoption of our technology by leading electrophysiologists,
both for daily clinical practice and scientific discovery. This year we are
seeing an important increase in utilization for applications such as
ventricular tachycardia and navigation of the unpredictable anatomy associated
with congenital heart disease. Our customers report that magnetic navigation
is uniquely suited to these important market segments, highlighting the
platform's versatility in every chamber. We are confident that it will
continue to transform interventional medicine well into the future."
Heart Rhythm 2009, the Heart Rhythm Society's 30th Annual Scientific
Sessions, will be held at the Boston Convention and Exhibition Center, May 13
-- 16, 2009.
About Stereotaxis
Stereotaxis designs, manufactures and markets an advanced cardiology
instrument control system for use in a hospital's interventional surgical
suite to enhance the treatment of arrhythmias and coronary artery disease. The
Stereotaxis system is designed to enable physicians to complete more complex
interventional procedures by providing image guided delivery of catheters and
guidewires through the blood vessels and chambers of the heart to treatment
sites. This is achieved using computer-controlled, externally applied magnetic
fields that govern the motion of the working tip of the catheter or guidewire,
resulting in improved navigation, shorter procedure time and reduced x-ray
exposure. The core components of the Stereotaxis system have received
regulatory clearance in the U.S., Europe, Canada and elsewhere.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words "believe,"
"estimate," "project," "expect" or similar expressions. Forward-looking
statements inherently involve risks and uncertainties that could cause actual
results to differ materially from the forward-looking statements. Factors
that would cause or contribute to such differences include, but are not
limited to, continued acceptance for the Company's products in the
marketplace, the effect of global credit and economic conditions on the
ability and willingness of customers to purchase our systems, competitive
factors, changes in government reimbursement procedures, dependence upon
third-party vendors, timing of regulatory approval and return of the irrigated
catheter to the market, and other risks discussed in the Company's periodic
and other filings with the Securities and Exchange Commission. By making
these forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of this
release. There can be no assurance that the Company will recognize revenue
related to its purchase orders and other commitments in any particular period
or at all because some of these purchase orders and other commitments are
subject to contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified or canceled,
either by their express terms, as a result of negotiations, or by project
changes or delays.
SOURCE Stereotaxis, Inc.
-0- 05/11/2009
/CONTACT: Jim Stolze, Chief Financial Officer of Stereotaxis, Inc.,
+1-314-678-6105; or Investors, Doug Sherk or Jenifer Kirtland,
+1-415-896-6820, or Media, Steve DiMattia, +1-646-201-5445, all of EVC Group,
Inc., for Stereotaxis, Inc./
/Web Site: http://www.stereotaxis.com /
(STXS)
CO: Stereotaxis, Inc.; Heart Rhythm 2009; Heart Rhythm Society
ST: Missouri, Massachusetts
IN: HEA MTC
SU: TDS
PR
-- SF14891 --
6491 05/11/200916:04 EDThttp://www.prnewswire.com